Transgenic antithrombin III (Genzyme).

  title={Transgenic antithrombin III (Genzyme).},
  author={Pollen K Yeung},
  journal={IDrugs : the investigational drugs journal},
  volume={3 6},
  • Pollen K Yeung
  • Published 2000 in IDrugs : the investigational drugs journal
ATIII LLC, a joint venture between Genzyme Transgenics (GTC) and Genzyme General, is developing transgenic recombinant human antithrombin III (rhAT-III) as a potential treatment for sepsis and other disorders involving thrombosis. It is in phase III clinical trials in the US and Europe as an anticoagulant in patients undergoing elective cardiac surgery… CONTINUE READING